Therapeutic targeting of MLL
AUTOR(ES)
Liedtke, Michaela
FONTE
American Society of Hematology
RESUMO
Treatment of hematologic malignancies is evolving from a uniform approach to targeted therapies directed at the underlying molecular abnormalities of disease. The mixed lineage leukemia (MLL) proto-oncogene is a recurrent site of genetic rearrangements in acute leukemias; and since its discovery in 1992, many advances have been made in understanding its role in leukemogenesis. A variety of MLL translocation partners have been described, and detailed structure/function studies have identified functional domains that are required for transformation. Proteins associated with the MLL core complex or its fusion partners have been isolated and characterized for their critical roles in leukemia pathogenesis. Downstream mediators of MLL transcriptional regulation and multiple collaborating signaling pathways have been described and characterized. These advances in our understanding of MLL-related leukemogenesis provide a foundation for ongoing and future efforts to develop novel therapeutic strategies that will hopefully result in better treatment outcomes.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2699228Documentos Relacionados
- Targeting CD40L: a Promising Therapeutic Approach
- Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?
- Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors*S⃞
- Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia
- Current Concepts in Therapeutic Strategies Targeting Cognitive Decline and Disease Modification in Alzheimer’s Disease